Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00952198 · ClinicalTrials.gov registry record · Phase 1

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

A Phase 1 study of Type 2 Diabetes, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 1
Development phase
128
Enrollment target
2
Study locations

NCT00952198 is a Phase 1 study of Type 2 Diabetes that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 128 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00952198, a Phase 1 study of Type 2 Diabetes, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
128 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be enrolled in this study.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Placebo; oral
  • DRUG ARRY-403, glucokinase activator; oral

Study Locations (2)

California

  • Profil Institute for Clinical Research - Chula Vista

Texas

  • Cetero - San Antonio

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2009-08
Est. Completion 2010-08
Phase Phase 1

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer

21 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00952198

The ClinicalTrials.gov registry entry for NCT00952198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (88% lower). The listed sponsor is Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo; oral is the first listed.

NCT00952198 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT00952198 about?

NCT00952198 is a clinical study titled "A Safety Study of ARRY-403 in Patients With Type 2 Diabetes". This is a Phase 1 study, involving a 10-day dosing period, designed to test the safety of investigational study drug ARRY-403 (as monotherapy or in addition to stable metformin therapy) in patients with Type 2 diabetes. Approximately 128 patients from the US will be enrolled in this study.

What is the current status of trial NCT00952198?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2009-08. Estimated completion is 2010-08.

What conditions does trial NCT00952198 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT00952198?

The interventions under investigation include: Placebo; oral (DRUG), ARRY-403, glucokinase activator; oral (DRUG).

Who is sponsoring clinical trial NCT00952198?

This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00952198 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.